A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

Table 4 Main characteristics, therapy, and outcomes of patients with SAB (clinical evaluable population)

Age, years, gender	Source of infection	Pathogen	Days of IV therapy	Agent	Microbiological response	Clinical response
Telavancin, n = 8
55, male	Peripherally inserted central catheter	MRSA	15	Telavancin	Eradication	Cure
55, male	Central IV catheter	MRSA	14	Telavancin	Eradication	Cure
74, male	Peripheral IV catheter	MRSA	14	Telavancin	Eradication	Cure
37, male	Central IV catheter	MRSA	14	Telavancin	Eradication	Cure
53, male	Cellulitis, associated with a previous peripheral IV catheter	MSSA	12	Telavancin	Eradication	Cure
63, female	Central IV catheter	MRSA	13	Telavancin	Eradication	Cure
56, female	Central IV catheter	MSSA	15	Telavancin	Eradication	Cure
73, female	Peripheral IV catheter	MSSA	15	Telavancin	Relapse	Failure
Standard therapy, n = 9
25, female	Cellulitis	MRSA	15	Vancomycin	Relapse	Cure
59, male	Peripheral IV catheter	MRSA	14	Vancomycin	Eradication	Cure
87, female	Peripherally inserted central catheter	MSSA	14	Vancomycin	Eradication	Cure
75, male	N/A	MSSA	15	ASP	Relapse	Failure
55, female	Peripherally inserted central catheter	MSSA	15	Vancomycin	Eradication	Cure
83, female	Decubitus ulcer	MRSA	13	Vancomycin	Eradication	Cure
50, female	Central IV catheter	MSSA	15	ASP	Eradication	Cure
75, male	Central IV catheter	MSSA	15	ASP	Eradication	Cure
53, male	Central IV catheter	MRSA	13	Vancomycin	Eradication	Cure

ASP, anti-staphylococcal penicillin; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; N/A, not available; SAB, Staphylococcus aureus bacteremia.

ISSN: 1471-2334